Barrios-Garay K, Agudelo-Sánchez LF, Aguirre-Urizar JM, Gay-Escoda C. Analyses of odontogenic tumours: the most recent classification proposed by the World Health Organization (2017). Med Oral Patol Oral Cir Bucal. 2020 Nov 1;25 (6):e732-8.


doi:10.4317/medoral.23751

https://dx.doi.org/doi:10.4317/medoral.23751


1. El-Naggar AK, Chan JKC, Grandis JR, Takata T, Slootweg P, eds. WHO classification of head and neck tumours. 4th ed. Lyon: IARC Press; 2017.

2. Pindborg JJ, Kramer IRH, Torloni H. WHO histological typing of odontogenic tumours, jaw cysts, and allied lesions. Geneva: World Health Organization; 1971.

3. Kramer IRH, Pindborg JJ, Shear M. WHO histological typing of odontogenic tumors. 2nd ed. Berlin: Springer-Verlag; 1992.

https://doi.org/10.1007/978-3-662-02858-2

4. Barnes L, Eveson J, Reichart P, Sidransky D, eds. World Health Organization classification. Pathology and genetics of head and neck tumors. 3rd ed. Lyon: IARC Press; 2005.

5. Wright JM, Odell E, Speight PM, Takata T. Odontogenic tumors, WHO 2005: Where do we go from here?. Head Neck Pathol. 2014;8:373-82.

https://doi.org/10.1007/s12105-014-0585-x

PMid:25409849 PMCid:PMC4245407

6. Wright JM, Vered M. Update from the 4th Edition of the World Health Organization classification of head and neck tumours: Odontogenic and maxillofacial bone tumors. Head Neck Pathol. 2017;11:68-77.

https://doi.org/10.1007/s12105-017-0794-1

PMid:28247226 PMCid:PMC5340735

7. Kennedy RA. WHO is in and WHO is out of the mouth, salivary glands, and jaws section of the 4th edition of the WHO classification of head and neck tumours. Br J Oral Maxillofac Surg. 2018;56:90-5.

https://doi.org/10.1016/j.bjoms.2017.12.009

PMid:29352614 

8. Ebell MH, Siwek J, Weiss BD, Woolf SH, Susman J, Ewingman B, et al. Strength of recommendation taxonomy (SORT): A patient centered approach to grading evidence in the medical literature. J Am Board Fam Pract. 2004;17:59-67.

https://doi.org/10.3122/jabfm.17.1.59

PMid:15014055 

9. Moher D, Liberati A, Tetzlaff J, Altman DG. The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoSMed. 2009;6:e1000097.

https://doi.org/10.1371/journal.pmed.1000097

PMid:19621072 PMCid:PMC2707599

10. Koutlas IG, Allen CM, Warnock GR, Manivel JC. Sclerosing odontogenic carcinoma: A previously unreported variant of a locally aggressive odontogenic neoplasm without apparent metastatic potential. Am J Surg Pathol. 2008;39:1613-19.

https://doi.org/10.1097/PAS.0b013e31817a8a58

PMid:18753945 

11. Ide F, Kikuchi K, Kusama K. Sclerosing odontogenic carcinoma. Pathol Int. 2011;61:259-61.

https://doi.org/10.1111/j.1440-1827.2011.02648.x

PMid:21418400 

12. Hussain O, Rendon AT, Orr RL, Speight PM. Sclerosing odontogenic carcinoma in the maxilla: A rare primary intraosseous carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;116:e283-e6.

https://doi.org/10.1016/j.oooo.2013.01.018

PMid:23567261 

13. Mosqueda-Taylor A, Pires FR, Aguirre-Urízar JM, Carlos-Bregni R, de la Piedra-Garza JM, Martínez-Conde R, et al. Primordial odontogenic tumour: Clinicopathological analysis of six cases of a previously undescribed entity. Histopathology. 2014;65:606-12.

https://doi.org/10.1111/his.12451

PMid:24807692 

14. Lei Y, Jaradat JM, Owosho A, Adebiyi KE, Lybrand KS, Neville BW, et al. Evaluation of SOX2 as a potential marker for ameloblastic carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014;117:608-16.

https://doi.org/10.1016/j.oooo.2014.01.017

PMid:24603057 

15. Richardson MS, Muller S. Malignant odontogenic tumors: An update on selected tumors. Head Neck Pathol. 2014;8:411-20.

https://doi.org/10.1007/s12105-014-0584-y

PMid:25409848 PMCid:PMC4245406

16. Gong Y, Wang L, Wang H, Li T, Chen X. The expression of NF-κβ, Ki-67 and MMP-9 in CCOT, DGCT and GCOC. Oral Oncol. 2009;45:515-20.

https://doi.org/10.1016/j.oraloncology.2008.07.004

PMid:18723387 

17.Yancoskie AE, Sreekantaiah C, Jacob J, Rosenberg A, Edelman M, Antonescu CR, et al. EWSR1 and ATF1 rearrangements in clear cell odontogenic carcinoma: Presentation of a case. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014;118:e115-e8.

https://doi.org/10.1016/j.oooo.2014.02.004

PMid:24721473 

18. Mosqueda-Taylor A, Neville BW, Tatemoto Y, Ogawa I, Takata T. Odontogenic carcinoma with dentinoid: A new odontogenic carcinoma. Head Neck Pathol. 2014;8:421-31.

https://doi.org/10.1007/s12105-014-0586-9

PMid:25409850 PMCid:PMC4245409

19. Chikosi R, Segall N, Augusto P, Freedman P. Odontogenic carcinosarcoma: Case, report and literature review. J Oral Maxillofac Surg. 2011;69:1501-7.

https://doi.org/10.1016/j.joms.2010.05.071

PMid:21195529 

20. Sweeney RT, McClary AC, Myers BR, Biscocho J, Neahring L, Kwei KA, et al. Identification of recurrent SMO and BRAF mutations in ameloblastomas. Nat Genet. 2014;46:722-5.

https://doi.org/10.1038/ng.2986

PMid:24859340 PMCid:PMC4418232

21. Kurppa KF, Caton J, Morgan PR, Ristimaki A, Ruhin B, Kellokoski J, et al. High frequency of BRAF V600E mutations in ameloblastoma. J Pathol. 2014;232:492-8.

https://doi.org/10.1002/path.4317

PMid:24374844 PMCid:PMC4255689

22. Diniz MG, Gomes CC, Guimarães BV, Castro WH, Lacerda JC, Cardoso SV, et al. Assessment of BRAFV600E and SMOF412E mutations in epithelial odontogenic tumours. Tumour Biol. 2015;36:5649-53.

https://doi.org/10.1007/s13277-015-3238-0

PMid:25854168 

23. Pereira NB, Pereira KM, Coura BP, Diniz MG, de Castro WH, Gomes CC, et al. BRAFV600E mutation in the diagnosis of unicystic ameloblastoma. J Oral Pathol Med. 2016;45:780-5.

https://doi.org/10.1111/jop.12443

PMid:27084044 

24. Dissanayake RK, Jayasooriya PR, Siriwardena DJ, Tilakaratne WM. Review of metastasizing (malignant) ameloblastoma (METAM): Pattern of metastasis and treatment. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011;111:734-41.

https://doi.org/10.1016/j.tripleo.2010.12.018

PMid:21459020 

25. Kaye FJ, Ivey AM, Drane WE, Mendehall WM, Allam RW. Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma. J Natl Cancer Inst. 2015;107:dju378.

https://doi.org/10.1093/jnci/dju378

PMid:25475564 

26. Broudic M, Blay JY, Vazquez L, Evrard A, Karanian M, Taïeb S, et al. Persistent response to vemurafenib in metastatic ameloblastoma with BRAF mutation: A case report. J Med Case Rep. 2019;13:245-63.

https://doi.org/10.1186/s13256-019-2140-6

PMid:31340860 PMCid:PMC6657072

27. Buchner A, Vered M. Ameloblastic fibroma: A stage in the development of a hamartomatous odontoma or a true neoplasm? Critical analysis of 162 previously reported cases plus 10 new cases. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;116:598-606.

https://doi.org/10.1016/j.oooo.2013.06.039

PMid:24055148